Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority of treated patients, however, develop resistance and disease progression and there is a critical need to identify novel t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Kregel, Steven, Chen, James L., Tom, Westin, Krishnan, Venkatesh, Kach, Jacob, Brechka, Hannah, Fessenden, Tim B., Isikbay, Masis, Paner, Gladell P., Szmulewitz, Russell Z., Vander Griend, Donald J.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5041979/
https://ncbi.nlm.nih.gov/pubmed/27036029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8456
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados